Boston Scientific Corporation (NYSE: BSX) announces the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. “Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence,” said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. The purchase price of $71 cash per share represents an equity value of $3.7 billion and an enterprise value of $3.3 billion.
Read the full article: Boston Scientific Closes Acquisition of Axonics, Inc. //
Source: https://www.prnewswire.com/news-releases/boston-scientific-closes-acquisition-of-axonics-inc-302307088.html